Clinical trial · Interventional
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
the Effectiveness and Safety Study on PD-1 Combined With Pyrotinib for First-line Chemotherapy Failed HER2 Insertion Mutation Advanced Non-small Cell Lung Cancer
NCT04144569CI-TRIAL-00080551recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2 Insertion Mutation Positive Advanced NSCLC | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 Combined With Pyrotinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PD-1 Combined With Pyrotinib
- description
- PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
- interventionNames
- Drug: PD-1 Combined With Pyrotinib
Primary outcomes (1)
- measure
- PFS
- timeFrame
- Approximately 1 years
- description
- Progression free survival
Secondary outcomes (2)
- measure
- ORR
- timeFrame
- Approximately 1 years
- description
- To measure the patients's overall response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced non-small cell lung cancer confirmed by histology or cytology * HER2 insertion mutation-positive * Failure with first-line standard chemotherapy * with measurable lesions. Exclusion Criteria: * no measurable tumor lesions * Patients received PD-1 or Pyrotinib before
References
Publications (0)
Data not yet available
No reference posted for this study.